Presented interim data from the ongoing Phase 1 dose escalation study of PRT3789, its first-in-class IV SMARCA2 degrader, ...

In a report released today, Peter Lawson from Barclays maintained a Sell rating on Prelude Therapeutics (PRLD – Research Report), with a price target of $1.00. The company’s shares closed yesterday at ...

Analyst Reni Benjamin from JMP Securities reiterated a Buy rating on Prelude Therapeutics (PRLD – Research Report) and keeping the price ...

WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, has shared its third-quarter ...

Barclays analyst Peter Lawson lowered the firm’s price target on Prelude Therapeutics (PRLD) to $1 from $3 and keeps an ...

On Thursday, Prelude Therapeutics Inc (PRLD) stock saw a decline, ending the day at $1.2 which represents a decrease of $-0.12 or -9.09% from the prior close of $1.32. The stock opened at $1.31 and ...

Prelude Therapeutics (NASDAQ:PRLD – Get Free Report) ‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research report issued to clients and ...

Interim data from ongoing trial of PRT3789 showed additional clinical activity at higher doses in patients with non-small ...

PRLD stock touches 52-week low at $1.32 amid market challenges Prelude Therapeutics Inc (PRLD) stock has reached a 52-week low, trading at $1.32, as the biopharmaceutical company faces a ...

WILMINGTON, Del., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision ...